Finance

Lists
NGEN:NASDAQ
NervGen Pharma Corp
$1.74
+2.06%
(+0.035) 1D
Aug 11, 12:03:41 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NGEN...
Open
$1.71
High
$1.76
Low
$1.71
Mkt. cap
184.78M
Avg. vol.
644.38K
Volume
55.02K
52-wk high
$6.30
52-wk low
$1.58
EPS
-$0.41
Beta
0.71
Shares outstanding
82.19M
No. of employees
10
Open
$1.71
High
$1.76
Low
$1.71
Mkt. cap
184.78M
Avg. vol.
644.38K
Volume
55.02K
52-wk high
$6.30
52-wk low
$1.58
EPS
-$0.41
Beta
0.71
Shares outstanding
82.19M
No. of employees
10
About NervGen Pharma Corp
CEO-
Employees10
Founded2017
HeadquartersVancouver, British Columbia, Canada
SectorPharmaceutical industry
Websitenervgen.com
Analyst ratings
Based on 4 analysts giving stock ratings to NGEN in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for NGEN in the last 3 months.
Highest
Current $1.74
$15.00 (+764.55%)
Average
$10.33 (+495.39%)
Lowest
$6.00 (+245.82%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$15.00
+764.6%
07/14/2026
Marc Goodman
Leerink Partners
Buy
Initiated
$10.00
+476.4%
07/13/2026
Joseph Thome
TD Cowen
Buy
Initiated
-
-
06/11/2026
Justin Keywood
Stifel Nicolaus
Buy
Reiterated
$6.00
+245.8%
05/21/2026
Elemer Piros
Lucid Capital
Buy
Initiated
$18.00
+937.5%
04/15/2026
Andre Uddin
Research Capital
Buy
Maintained
$5.50
+217%
04/10/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
$12.00
+591.6%
04/09/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.71M
4.44M
3.60M
4.86M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.76M
1.73M
2.80M
2.67M
Operating expense
6.47M
6.17M
6.40M
7.53M
Total operating expenses
6.47M
6.17M
6.40M
7.53M
Operating income
-6.47M
-6.17M
-6.40M
-7.53M
Other non operating income
-2.70M
1.98M
-20.24M
5.72M
EBT including unusual items
-9.10M
-4.16M
-26.91M
-1.68M
EBT excluding unusual items
-9.10M
-4.16M
-26.91M
-1.68M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.10M
-4.16M
-26.91M
-1.68M
Net profit margin
-
-
-
-
Earnings per share
-0.13
-0.06
-
-
Interest and investment income
86.90K
77.07K
61.68K
104.07K
Interest expense
-
-
-
-
Net interest expenses
86.90K
77.07K
61.68K
104.07K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.46M
-6.16M
-6.39M
-7.52M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps